Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Xilio Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 24 | 1 | 27 | +4 |
| Shares | 2.62M | 4.21K | 3.41M | +792.0K (+30.3%) |
| Value | $22.0M | $35.4K | $32.6M | +$10.6M (+48.4%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Xilio Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| OrbiMed Advisors LLC | 592,300 | $5.67M | 0.11% |
| Adage Capital Partners GP, L.L.C. | 111,541 | $1.07M | 0.00% |
| Citadel Advisors LLC | 25,950 | $248.6K | 0.00% |
| Bridgeway Capital Management, LLC | 17,544 | $168.1K | 0.00% |
| Two Sigma Investments, LP | 14,544 | $139.3K | 0.00% |
| Prelude Capital Management, LLC | 11,600 | $111.1K | 0.01% |
| BlackRock, Inc. | 8,757 | $83.9K | 0.00% |
| Steward Partners Investment Advisory, LLC | 714 | $6.84K | 0.00% |
| Security National Bank of Sioux City Iowa | 321 | $3.08K | 0.00% |
| Barclays PLC | 115 | $1.10K | 0.00% |
| Jones Financial Companies LLLP | 29 | $262 | 0.00% |
Sold out (7)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Caligan Partners LP | 112,128 | $943.0K |
| AJU IB Investment Co., Ltd. | 47,695 | $401.1K |
| FMR LLC | 36,558 | $307.5K |
| Ghisallo Capital Management LLC | 13,800 | $116.1K |
| JPMorgan Chase & Co | 240 | $1.98K |
| Vanguard Global Advisers, LLC | 210 | $1.77K |
| Royal Bank of Canada | 91 | $1.00K |
Not filed for Q2 2026 yet (1)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 4,206 | $35.4K |